RecruitingNot ApplicableNCT04185272
Butyrophilins Role in Colon Cancer
Role of Butyrophilins in Colon Cancers Aggressiveness Evaluation
Sponsor
Institut Paoli-Calmettes
Enrollment
200 participants
Start Date
Jun 30, 2020
Study Type
INTERVENTIONAL
Conditions
Summary
quantification of BTNL molecules in colon cancer in order to determinate if their could be used as a prognostic marquer
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is investigating the role of proteins called butyrophilins — part of the immune system — in colon cancer. Blood and tumor tissue samples are collected from patients undergoing colon cancer surgery to better understand how the immune system responds to cancer.
**You may be eligible if...**
- You are over 18 years old
- You have been diagnosed with non-metastatic colon cancer that can be surgically removed, OR metastatic colon cancer where a combined colon and liver surgery has been planned
- You are in good physical condition (Performance Status 0 or 1)
**You may NOT be eligible if...**
- You have cancer that cannot be surgically removed
- You have a serious coexisting medical condition that would make surgery unsafe
- You are not affiliated with a social security system (in France)
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALanalysis of BTN and BTNL status
analysis of BTN and BTNL expression in colon cancer and hepatic metastasis
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04185272